This case involves a qui tam action brought under the False Claims Act by Omni Healthcare, a medical practice, on behalf of the United States and numerous states. Omni alleged that MD Spine Solutions LLC, a clinical laboratory, committed Medicare fraud by submitting claims for Polymerase Chain Reaction (PCR) urinary tract infection (UTI) tests that were medically unnecessary. The dispute centered on the regulatory framework of Medicare, which reimburses providers for services that are 'reasonable and necessary.' While Medicare has National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) to guide these decisions, none existed for the specific PCR UTI testing at issue. Omni argued that PCR tests were more expensive than the traditional 'gold standard' bacterial urine culture tests but offered no greater clinical benefit, rendering them unnecessary. The case also involved a specific email exchange between MD Labs' founders discussing billing practices and a request for guidance on medical necessity, which Omni claimed showed the lab's awareness of potential fraud. The district court granted summary judgment to MD Labs, finding that Omni failed to prove the lab 'knowingly' submitted false claims.
The First Circuit focused on the element of 'scienter'—the requirement that a defendant 'knowingly' present a false claim. The court defined scienter to include actual knowledge, deliberate ignorance, or reckless disregard of the truth or falsity of the information. The court established a new principle for the First Circuit: in FCA cases alleging Medicare fraud based on laboratory testing, a laboratory can generally rely on a doctor's order to show that a test is 'reasonable and necessary.' This reliance creates a safe harbor, meaning the burden shifts to the relator to rebut this showing. The court reasoned that laboratories do not treat patients and lack the expertise to make medical necessity determinations; that role belongs to the ordering physician. The court found that Omni's evidence was insufficient to overcome this reliance. The internal emails between MD Labs' founders discussed billing rates and the need for guidance on medical necessity, but the court held these did not prove the founders knew the tests were medically unnecessary. The court noted that one founder's suggestion to ask for guidance on medical necessity did not equate to an admission of risk that claims were false. Furthermore, the court rejected Omni's argument regarding the lack of NCDs or LCDs, noting that individual adjudication can fill that gap. Finally, regarding the 'bundling' of tests, the court found that MD Labs provided expert testimony supporting the medical reasonableness of the test panels, and Omni failed to provide counter-evidence to rebut this expert opinion. The court concluded that Omni offered only speculation and failed to demonstrate a genuine issue of material fact regarding the lab's state of mind.
This decision provides a significant safe harbor for clinical laboratories facing False Claims Act litigation. Labs can now generally defend against 'medically unnecessary' claims by pointing to the ordering physician's requisition, rather than having to independently verify the medical necessity of every test. This shifts the evidentiary burden to relators, who must now produce specific evidence that the lab had a 'specific basis to second-guess' the doctor's order or engaged in a scheme to encourage unnecessary testing. The ruling clarifies that the absence of specific Medicare coverage determinations does not automatically imply a lab should have known a test was unnecessary. The case was affirmed, and the parties bear their own costs.
Podcast (federal-narrative-summaries): Play in new window | Download